Neuroblastome
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | DIS-NEUROBLASTOMA |
|---|---|
| Type | Maladie |
| Alias | Tumeur neuroblastique périphérique pédiatriqueTumeur embryonnaire du système neuro-sympathiqueНейробластома |
| État | reviewed 2026-05-20 | pending_clinical_signoff |
| Maladies | Aucune déclaration |
| Sources | SRC-NCCN-PEDIATRIC-SARCOMA |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9500/3 |
|---|---|
| icd_o_3_topography | ["C74.9", "C47", "C48"] |
| icd_10 | C74.9 |
| who_classification | WHO Endocrine Tumours 5th ed (2022): Neuroblastoma — peripheral neuroblastic tumor of sympathetic-nervous-system origin; INSS + INRG staging; MYCN amplification + ALK alterations are key prognostic + targetable |
Notes
COG + SIOPEN risk-stratified treatment frameworks. Anti-GD2 immuno- therapy (dinutuximab + cytokines) is high-risk standard since 2009; ch14.18/Naxitamab as alternative. Lorlatinib + crizotinib for ALK- mutant subset (cooperative-group trials). MIBG-iodine131 + lutathera therapy for MIBG-avid relapsed disease. Surveillance for syndromic predisposition carriers: abdominal US + urinary catecholamines q3-6mo to age 8 in Costello + Beckwith-Wiedemann.
Utilisé par
No reverse references found in the YAML corpus.